KPV 10MG

KPV is a tripeptide (Lysine-Proline-Valine) that represents the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH). It’s one of the smallest known peptides with biological activity and has been studied primarily for anti-inflammatory properties.

Research background:

• Preclinical studies (largely animal and cell-culture models) suggest KPV can reduce inflammation by inhibiting NF-κB signaling, a pathway central to inflammatory response.

• It’s been studied in models of inflammatory bowel disease (colitis), skin inflammation, and wound healing, with some research also looking at antimicrobial properties.

• Notably, unlike full α-MSH, KPV doesn’t appear to significantly affect pigmentation or have the hormonal effects tied to the melanocortin receptors that control skin tanning — this is part of what made it interesting to isolate and study separately.

• Human clinical trial data is limited; most evidence comes from animal models and in vitro studies, not large-scale human trials.

Important caveats:

• KPV is not FDA-approved for any therapeutic use. It’s sold as a research chemical, typically labeled “not for human consumption.”

• No established human dosing, purity standards, or long-term safety data exist for self-administration.

• Marketing claims about anti-inflammatory or skin benefits in humans are extrapolated from preclinical data, not confirmed clinical outcomes.